If AXL kinase plays an important role in DT cell survival in ALK-rearranged cancer, the dual inhibition of ALK and AXL by gilteritinib might delay the emergence of additional acquired resistance and represent an important clinical option. The gene discussed is ALK; the disease is cancer.